Narrative review / 2024
A review highlights that therapies achieving robust and sustained LDL-C reduction can reduce atherosclerotic cardiovascular disease risk.
This review examines the role of early, intensive, and sustained LDL-C lowering for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Cumulative exposure to LDL-C drives ASCVD risk, and no established LDL-C threshold exists below which clinical benefits cease or safety concerns arise. Interventions discussed include lifestyle modifications, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, siRNA therapy, evinacumab, and emerging agents.
- Study type
- Narrative review
- Who was studied
- Patients indicated for primary or secondary ASCVD prevention
- What was measured
- Atherosclerotic cardiovascular disease (ASCVD) risk reduction and LDL-C lowering
THE PAPER
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.
Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. Am J Prev Cardiol, 2024.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.